AX-024 HCl can inhibit cytokine release especially the production of IL-6, TNFα, IFN-γ, IL-10 and IL-17A. It also modulates TCR signaling and prevents psoriasis and asthma.

IFN alpha-IFNAR-IN-1 HCl is a nonpeptidic, low-molecular-weight inhibitor of the interaction between IFN-α and IFNAR and inhibit MVA-induced IFN-α responses by BM-pDCs (IC50=2-8 μM).

BMS-986165 is a highly selective and allosteric TYK2 inhibitor. It is a high affinity JH2 ligand with Ki values of 0.02 nM and 1nM for binding to Tyk2 pseudokinase domain and JAK1 pseudokinase (JH2) domain, respectively. It blocked receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain.

SM-276001 is a selective and potent TLR7 agonist. SM-276001 is can induce antitumor immune responses when dosed either intratracheally or orally. Oral administration of SM-276001 leads to the induction of IFNα, TNFα and IL-12p40 and a reduction in tumor burden in the Balb/c syngeneic Renca and CT26 models.

Dasatinib is a potent and dual Abl/ Src inhibitor IC50 of < 1 nM/0.8 nM respectively and also inhibits c-Kit (WT)/c-Kit (D816V) with IC50 of 79 nM/37 nM.